title: [An in-vivo evaluation of Brilliant Blue G in macular surgery].
abstract: OBJECTIVE
  The aim of this study was to evaluate the functional outcome of Brilliant Blue G (BBG) and the staining properties in macular surgery.
  
  
  METHODS
  BBG was applied during vitrectomy for macular holes (n = 21) or epiretinal membranes (n = 18) in a prospective, non-comparative consecutive series of patients (Brilliant Peel®; Fluoron® GmbH, Neu-Ulm, Germany). Before and after surgery all patients underwent a complete clinical examination including measurement of best corrected visual acuity and intraocular pressure, perimetry, fundus photography and optical coherence tomography.
  
  
  RESULTS
  Vitrectomy was performed in combination with a cataract operation in 14 patients. All macular holes were closed successfully. Visual acuity was in average 0.16 preoperatively in macular hole cases and increased up to 0.4 after 6 months. Visual acuity of patients with epiretinal membranes changed on average from 0.3 to 0.45 after 6 months. The retina thickness in patients with epiretinal membranes was initially 402.6 µm according to the OCT and 304.7 µm after 6 months postoperatively. No toxic effects attributable to the dye were noted during patient follow-up, especially all perimetry tests were normal.
  
  
  CONCLUSIONS
  Brilliant blue provides a sufficient and selective staining of the ILM. No retinal toxicity or adverse effects related to the dye were observed in this study. The long-term safety of this dye will have to be evaluated in larger patient series and a longer follow-up.
authors.affiliation: Augenklinik der LMU, Campus Innenstadt, Mathildenstrasse 8, Munich. anna.hoeing@med.unimuenchen.de
authors.forename: A
authors.initials: A
authors.lastname: Höing
authors.forename: M
authors.initials: M
authors.lastname: Remy
authors.forename: M
authors.initials: M
authors.lastname: Dirisamer
authors.forename: S
authors.initials: S
authors.lastname: Priglinger
authors.forename: C L
authors.initials: CL
authors.lastname: Schönfeld
authors.forename: A
authors.initials: A
authors.lastname: Kampik
authors.forename: C
authors.initials: C
authors.lastname: Haritoglou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002387:Cataract Extraction; D003131:Combined Modality Therapy; D019773:Epiretinal Membrane / Q000601:surgery*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007202:Indicators and Reagents; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis; D011446:Prospective Studies; D012167:Retinal Perforations / Q000601:surgery*; D012394:Rosaniline Dyes / Q000008:administration & dosage* / Q000633:toxicity; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D058609:Visual Field Tests; D014821:Vitrectomy
chemical_list: D007202:Indicators and Reagents; D012394:Rosaniline Dyes; C004692:coomassie Brilliant Blue